Ori, Jason, and Vincent discuss the use of antibodies to neutralize amyloid-β seeds before their deposition becomes detectable in transgenic mice, and the finding that the preclinical phase of Alzheimer‘s disease may be a late manifestation of earlier pathogenic seed formation.